Bms-907351
Metastatic Squamous Non-Small Cell Lung Carcinoma
University of Illinois at ChicagoPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
54 Active assets in the Metastatic Squamous Non-Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BBB |
Pembrolizumab Shanghai Henlius Biotech | Phase 3 | BB |
Serplulimab Shanghai Henlius Biotech | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BB |
Docetaxel Shanghai Henlius Biotech | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →